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Breast cancer is a complex phenotypically diverse genetic disease, involving a variety of changes in gene expression and structure.
Recent advances in molecular proﬁling technology have made great progress in unravelling the molecular taxonomy of breast
cancer, which has shed new light on the aetiology of the disease and also heralded great potential for the development of novel
biomarkers and therapeutic targets. Mi(cro)RNAs are a contemporary class of small noncoding endogenous RNA molecules,
generating great excitement in the clinical and scientiﬁc communities. The recent discovery that miRNA expression is frequently
dysregulated in cancer has uncovered an entirely new repertoire of molecular factors upstream of gene expression, which warrants
extensive investigation to further elucidate their precise role in malignancy. We present a comprehensive and timely review of the
role of miRNAs in cancer: addressing miRNA function, their putative role as oncogenes or tumor suppressors, with a particular
emphasis on breast cancer throughout. We discuss the recent discovery of quantiﬁable circulating cancer-associated miRNAs,
which heralds immense potential for their use as novel minimally invasive biomarkers for breast and other cancers. Finally, we
comment on the potential role of miRNAs in breast cancer management, particularly in improving current prognostic tools and
achieving the goal of individualized cancer treatment.
1.Introduction
The molecular biology of malignancy is diverse, complex,
and remains poorly understood. The incidence of malignan-
ciessuchasbreastcancerisincreasingconsistently,andbreast
cancer has now become the commonest form of female
malignancyamongwomeninalmostallofEuropeandNorth
America. Each year more than 1.3 million women will be
diagnosed with breast cancer worldwide and approximately
4652000 will die from the disease [1] despite the fact that
breast cancer is highly curable if diagnosed and treated
appropriately at an early stage. In Ireland alone, the annual
incidence is currently over 2300 and rising [2]. The value of
current histological prognostic indicators in predicting the
course of the disease is weak and many of the molecular
mechanisms underlying breast cancer progression remain
poorly understood. This deﬁcit has led to signiﬁcant interest
in the quest for novel predictive markers for breast cancer.
Mi(cro)RNAsareacontemporaryclassoftinynoncoding
endogenous RNA molecules, only 18–25 nucleotides long.
Since their discovery in 1993, these small molecules have
been shown to play critical regulatory roles in a wide range
of biological and pathological processes. Elucidating their
mechanisms of action is still in its infancy. Nonetheless,
work in this area to date has demonstrated that miRNAs
may regulate cellular gene expression at the transcriptional
or posttranscriptional level; by suppressing translation of
protein coding genes, or cleaving target mRNAs to induce
their degradation, through imperfect pairing with target
mRNAs of protein coding genes [3]. MiRNA biogenesis in
the human cell is a multistep complex process. A simpliﬁed
representationisshowninFigure 1[4].Thespeciﬁcregionof
miRNA importance for mRNA target recognition is located
at the 5  end of the mature miRNA sequence, from bases
2 to 8. This is often referred to as the “seed sequence”
[5]. Computational target prediction algorithms have been
developed to identify putative mRNA targets, and these place
considerable importance on this seed sequence, using it
to search for complementary sequences in the 3 -UTRs of
known genes that exhibit conservation across species. These2 Journal of Oncology
algorithms predict that each miRNA may potentially bind to
as many as 200 targets and estimate that miRNAs control the
expression of at least one third of human mRNAs, further
highlightingtheircrucialroleasregulatorsofgeneexpression
[6].
At the time of writing, 8273 mature miRNA sequences
have been described in primates, rodents, birds, ﬁsh, worms,
ﬂies, plants, and viruses [7]. This represents a growth of
over 200 microRNAs in the last 2 years. In the human
genome, over 600 mature miRNAs have been reported to
date; however, computational prediction estimates that this
could increase to >1000 [8]. It is obvious that the microRNA
story is just beginning.
2. ExperimentalTechniquesformiRNAAnalysis
The explosion of interest in miRNAs over the past two
years necessitates eﬀective tools for detecting their presence,
quantiﬁcation, and functional analysis. High-throughput
proﬁling techniques such as miRNA microarrays and bead-
based miRNA proﬁling have facilitated miRNA expression
proﬁling, that is, far superior to existing low through-put
techniques such as Northern blotting and cloning, and is
essential for validation of microarray data. Castoldi et al. [9]
described a novel miRNA microarray platform using locked
nucleic acid-modiﬁed capture probes. Locked nucleic acid
modiﬁcation improved probe thermostability and increased
speciﬁcity, thus enabling miRNAs with single nucleotide
diﬀerencestobediscriminated—animportantconsideration
as sequence-related family members may be involved in
diﬀerent physiologic functions [10]. An alternative high-
throughput miRNA proﬁling technique is the bead-based
ﬂow cytometric approach developed by Lu et al. [11]; a
method which oﬀers high speciﬁcity for closely related miR-
NAs because hybridization occurs in solution. Quantitative
real-time PCR methodologies have been widely applied to
miRNA research. To date, the most successful approach in
terms of speciﬁcity and sensitivity is a two-step approach
using looped miRNA-speciﬁc reverse transcription primers
and TaqMan probes from Applied Biosystems [12].
To complement these miRNA proﬁling assays and to
addressfunctionalquestionsnecessitatedthedevelopmentof
methodstomanipulatemiRNAexpression.2-O-Methylanti-
sense single-strand oligonucleotides and locked nucleic acid-
modiﬁed oligonucleotides have been developed as miRNA
inhibitors, making the suppression of endogenous miRNA
activity and its downstream eﬀect on mRNA expression
achievable both in vitro and in vivo [13–16]. The eﬀects of
target miRNA knockdown on cell morphology and function
can be determined using standard assays for processes such
as cell proliferation, migration, invasion, and angiogenesis.
MiRNA inhibition can be studied in animal models via
transfection with tumor cells treated with miRNA inhibitors
[17] or by the intravenous injection of “antagomirs” (2-
O-methyl-modiﬁed nucleotides with a cholesterol moiety
at the 3 -end [18]. The most recent development in the
ﬁeld of miRNA inhibition, led by Naldini and colleagues,
describes techniques to manipulate miRNA expression in
vivo by expressing decoy miRNA targets via lentiviral vectors
[19]. This new approach to examine loss-of-function in
vivo complements the results obtained by classic knockout
technology as described above. It allowsinhibition ofspeciﬁc
miRNAs by building in multiple diﬀerent decoys in the same
miRNA inhibitor. This exciting new development should
lead to answers for interesting functional questions with
clinical or therapeutic relevance. For example, one could
now potentially knock down the oncogenic proprieties of the
miR-17-92-1clusterwhichiswelldocumentedtobeinvolved
in human cancer [20]. This technique could also help one
examine the let-7 microRNA family—a large, well-known
t u m o rs u p p r e s s o rm i R N Af a m i l y[ 21] thereby providing
insights into the functional consequence of knocking down
all let-7 miRNAs [22].
MiRNA mimicry, a complementary technique to the
aforementioned miRNA inhibition, has recently been used
in vitro to identify the cellular processes and phenotypic
changesassociatedwithspeciﬁcmiRNAstransfectedintocell
lines [23]. Functional assays (e.g., proliferation, migration,
invasion, and angiogenesis) then allow us to determine the
eﬀectofmiRNAupregulationontumorigenicornontumori-
genic cell populations. These revolutionary technologies will
undoubtedly help us shed light on the functional roles of
miRNAs and hold immense potential for application to the
clinical arena as novel therapeutic targets.
2.1. MiRNA and Human Cancer. Early experimental work
into the regulatory role of miRNAs uncovered their impor-
tant role in various cellular processes such as diﬀerentiation,
cell growth, and cell death. These processes are commonly
dysregulated in cancer, implicating miRNAs in carcino-
genesis. The ﬁrst evidence of involvement of miRNAs in
malignancy came from the identiﬁcation of a translocation-
induced deletion at chromosome 13q14.3 in B-cell chronic
lymphocytic leukemia [24]. Loss of miR-15a and miR-16-1
from this locus results in increased expression of the anti-
apoptoticgeneBCL2.Intensifyingresearchinthisﬁeld,using
a range of techniques including miRNA cloning, quantitative
PCR, microarrays and bead-based ﬂow cytometric miRNA
expression proﬁling has resulted in the identiﬁcation and
conﬁrmation of abnormal miRNA expression in a number
of human malignancies including breast cancer (Table 1).
MiRNA expression has been observed to be upregulated
or downregulated in tumours compared with normal tis-
sue, supporting their dual role in carcinogenesis as either
“Oncomirs” or tumour suppressors respectively [11].
The ability to obtain miRNA expression proﬁles from
human tumors has led to remarkable insight and knowledge
regarding the developmental lineage and diﬀerentiation
statesoftumours.Evenwithinasingledevelopmentallineage
ithasbeenshownthatdistinctpatternsofmiRNAexpression
areobserved,thatreﬂectmechanismsoftransformation,and
further support the idea that miRNA expression patterns
encode the developmental history of human cancers. In
contrast to messenger RNA (mRNA) proﬁles it is possible
also to successfully classify poorly diﬀerentiated tumours
using these new miRNA expression proﬁles [24, 25]. This
hasexcitingimplicationsclinically,inthatmiRNAexpression
may accurately diagnose poorly diﬀerentiated tissue samplesJournal of Oncology 3
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Figure 1:MiRNAbiogenesis andprocessinginhumancells: the multistepprocess begins inthe nucleus where theRNase IIIenzyme Drosha,
coupled with its binding partner DGCR8, cleaves nascent miRNA transcripts (pri-miRNA) into ∼70 nucleotide precursors (pre-miRNA).
These pre-miRNAs consist of an imperfect stem-loop structure. Pre-miRNAs are then exported from the nucleus into the cytoplasm by
Exportin 5. In the cytoplasm, the hairpin precursors are cleaved by Dicer and its binding partner the transactivator RNA-binding protein
TRBP into a small, imperfect dsRNA duplex (miRNA:miRNA
∗) that contains both the mature miRNA strand and its complementary
strand. The miRNA strand is incorporated into the miRNP complex and targets complementary mRNA sequences, exerting its functionality
via mRNA cleavage or translational repression.
which proved to be of uncertain histological origin thus
facilitating treatment planning. Again in contrast to mRNA,
Lu et al. showed that even a modest number of miRNAs are
suﬃcient to classify human tumours and miRNAs remain
largely intact in routinely collected, formalin-ﬁxed, and
paraﬃn-embedded clinical tissues [11]. Such information
would eliminate the diagnostic uncertainty that previously
existed in this setting and will be particularly useful for
metastatic lesions of uncertain primary origin.
2.2. Breast Cancer and Genomic Signatures. Recent advances
in phenotyping and molecular proﬁling of human cancers
have greatly enhanced the diagnosis and biological clas-
siﬁcation of several tumors, in particular breast cancers
where this technology has enhanced disease classiﬁcation
beyond single-gene markers. Prior to this a very limited
armamentarium of prognostic markers beyond those oﬀered
by histopathological analysis was available in the clinical
arena. Pioneering work by Sorlie et al. [33–35] identi-
ﬁed microarray-generated gene expression signatures which
stratiﬁed breast cancers into intrinsic subtypes largely based
on their ER, progesterone (PR), and HER2/neu receptor
status. Subtypes were designated Luminal A, which strongly
expressed ER and/or PR,butwereHER2/neunegative;Lumi-
nal B, which were ER, PR, and HER2/neu (triple) positive;
Basal tumours which were ER, PR, and HER2/neu triple
negative; and an HER2 subset which was ER negative ER but
had high expression of several genes in the HER2/neu ampli-
con, including HER2 and GRB7. Survival analyses showed
signiﬁcantly diﬀerent outcome for patients depending on
their tumour subtype, emphasising the clinical relevance of
stratiﬁcation by such molecular proﬁling. This novel method
of disease stratiﬁcation based on the molecular taxonomy
of the breast tumour heralds the promise of improving
and individualizing patients’ treatment regimens [36]. Great
scientiﬁc endeavours in this ﬁeld of microarray-based gene
expression proﬁling are ongoing and intensifying, with the
aim of translating such technical advances to the clinical
arena, in providing us with a new tool for accurate molecular
diagnosisofbreastcancer[37].Onesuchapplicationrecently
has been the development by Paik et al. of a multigene assay
predictive of recurrence of tamoxifen-treated, node-negative
breast cancer (Oncotype DX)[ 38]. This, and other similarly
novel genomic tests (e.g., MammaPrint, Theros, MapQuant
Dx) prove the feasibility of accelerating the transition
between empirical and molecular medicine. Analogous to
the derivation of intrinsic subtypes of breast cancer from
gene expression signatures, it is predicted that in the very
near future miRNA signatures, which are currently showing
capability of accurately classifying tumours according to
currently available prognostic variables, will serve as novel
biomarkers and prognostic indicators thus providing strong
rationale for individualised treatment. Additionally it is
thought that miRNAs have the potential to improve greatly4 Journal of Oncology
Table 1: MiRNAs with altered expression in malignancy.
Tissue/tumor type Increased expression Decreased expression
Breast [26, 27] miR-21, miR-29b-2 miR-125b, miR-145 miR-10b,
miR-155, miR-17-5p, miR-27b
Ovarian [28, 29] miR-141, miR-200(a-c),
miR-221
let-7f, miR-140, miR-145,
miR199a, miR-424
Endometrial [30–32] miR-103, miR-107, miR-185,
miR-205, miR-210, miR-449
miR-99b, miR-152, miR-193,
miR-204, miR-221, let-7i
Glioblastoma [4, 25] miR-221, miR-21 miR-181a, miR-181b,
miR-181c
Chronic lymphocytic leukaemia [24] miR-15, miR-16
Lymphoma [4, 11] miR-155, miR-17-92cluster miR-15a
Colorectal [4, 11, 25]
miR-10a, miR-17-92 cluster,
miR-20a, miR-24-1,
miR-29b-2, miR-31
miR-143, miR-145, let-7
Thyroid [4, 25] miR-221, miR-222, miR-146,
miR-181b, miR-197, miR-346
Hepatocellular [4, 25] miR-18, miR-224 miR-199a, miR-195,
miR-200a, miR-125a
Testicular [11] miR-372, miR-373
Pancreatic [4, 11, 25]
miR-221, miR-376a, miR301,
miR-21, miR-24-2, miR-100,
miR-103-1,2, miR-107,
miR-125b-1
miR-375
Cholangiocarcinoma [25] miR-21, miR-141, miR-200b
Prostate [11] let-7d, miR-195, miR-203 miR-128a
Gastric [4, 11, 25] miR-223, miR-21, miR-103-2 miR-218-2
Lung [4, 11, 25] mir-17-92 cluster, miR-17-5p let-7 family
the precision of the recently derived genomic signatures,
given that miRNA proﬁles have superior accuracy to mRNA
proﬁling in this regard [11]. A comprehensive interrogation
of the breast cancer subclasses via miRNA expression proﬁl-
ingcouldfurthercharacterizethemolecularbasisunderlying
these subtypes, perhaps deﬁne more precise subsets of breast
cancer, and provide opportunities for the identiﬁcation of
novel targets that can be exploited for targeted therapy.
2.3. MiRNA and Breast Cancer. Elucidation of the molecular
mechanisms involved in breast cancer has been the subject
of extensive research in recent years, yet several dilemmas
and major challenges still prevail in the management of
breast cancer patients including unpredictable response and
development of resistance to adjuvant therapies. The emer-
gence of miRNAs as regulators of gene expression identiﬁes
them as obvious novel candidate diagnostic and prognostic
indicators, and potential therapeutic targets. Calin et al. [24]
showed that half of the known mature human miRNAs are
located in cancer-associated genomic regions, or fragile sites,
thus potentiating their role in cancer. A speciﬁc example
of this is the polycistron cluster miR-17-92 at the c13orf25
locusonchromosome13q31.Thislocusisknowntoundergo
loss of heterozygosity in a number of diﬀerent cancer types,
including breast cancer [39] .An u m b e ro fo t h e rm i R N A s
(miR-196 and miR-10a) are located in homeobox clusters,
which are known to be involved in the development of breast
cancer and associated with the malignant capacity of cancer
cells [40].
MiRNA expression studies in breast cancer indicate
their importance and potential use as disease classiﬁers
and prognostic tools in this ﬁeld. In their analysis of 76
breast tumour and 34 normal specimens, Iorio et al. [26]
identiﬁed 29 miRNAs that were diﬀerentially expressed in
breast cancer tissue compared to normal, and a further set
of 15 miRNAs that could correctly discriminate between
tumour and normal. In addition, miRNA expression cor-
related with biopathological features such as ER and PR
expression (miR-30) and tumour stage (miR-213 and miR-
203). The diﬀerential expression of several let-7 isoforms was
associated with biopathologic features including PR status
(let-7c), lymph node metastasis (let-7f-1, let-7a-3, let-7a-
2), or high proliferation index (let-7c, let-7d)i nt u m o u r
samples. Mattie et al. identiﬁed unique sets of miRNAs
associated with breast cancers currently deﬁned by their
HER2/neu or ER/PR status [27]. Signiﬁcantly, there was
overlap between the miRNAs identiﬁed in both studies. In
initial studies in our own Department, we have shown that
the expression levels of miR-195 and mir-154 are negatively
correlated with ER positivity in a cohort of early breast
cancers [41]. In another recent publication we were the
ﬁrst to identify reliable endogenous controls for analysis of
miRNA by RQ-PCR in human breast tissue [42], subsequent
to our validation of a two-gene normaliser (MRPL19 andJournal of Oncology 5
PPIA) for analysis of gene expression in primary breast tissue
[43].
3.CirculatingmicroRNAs: NovelMinimally
Invasive Biomarkers for Breast Cancer?
Current challenges in the management of breast cancer
include a continuing search for sensitive minimally invasive
markers that can be exploited to detect early neoplastic
changes thus facilitating the detection of breast cancer at an
early stage, as well as for monitoring the progress of patients
with breast cancer and their response to treatments. Existing
biomarkers for breast cancer have many inherent deﬁcien-
cies.Mammographyiscurrentlythegoldstandarddiagnostic
tool however it is not without limitations, including its use
of ionizing radiation and a false positive rate of 8–10% [44].
To date, only two markers have been established so far in
the routine assessment of breast cancer: ER (for predicting
response to endocrine therapies) and HER2 (for predicting
response to Trastuzumab) [45]. Although these markers are
currently available, ER and HER2 assessment is far from
perfect [46]. A number of circulating tumour markers (e.g.,
carcinoembryonic antigen [CEA] and carbohydrate antigen
15-3 [CA 15-3]) are used clinically in the management of
breast cancer, but the sensitivity of these markers is low, so
that they are not useful as screening tools [47] though they
have long been in clinical use as prognostic markers and to
monitor for disease progression or recurrence. Despite their
frequentuse,CEAandCa15.3remainpoormarkersforearly
stage disease with a documented preoperative sensitivity of
only 9.11 and 5.36, respectively, as documented by Uehara
et al. [48, 49].
The ideal biomarker should be easily accessible such that
it can be sampled relatively noninvasively, sensitive enough
to detect early presence of tumours in almost all patients and
absent or minimal in healthy tumour-free individuals.
There is also great need for the identiﬁcation of sensitive,
reliable and acceptable markers of response to neoadjuvant
and adjuvant therapies. MiRNAs have enormous potential to
serve as an idea class of cancer biomarkers for the following
reasons.
(1) MiRNA expression is known to be aberrant in cancer
[11, 24].
(2) MiRNA expression proﬁles are pathognomonic, or
tissue-speciﬁc [11].
(3) MiRNAs are remarkably stable molecules that have
been shown to be well preserved in formalin ﬁxed,
paraﬃn embedded tissues as well as fresh snap frozen
specimens [50, 51].
Acknowledging the exceptional stability of miRNAs in
visceral tissue very recently instigated eﬀorts to establish if
miRNAs were also preserved, detectable, and quantiﬁable
in the circulation and other bodily ﬂuids (urine, saliva,
etc.). This area of miRNA research is only now emerging,
and is generating much excitement in clinical and scientiﬁc
communities, such as its potential. MiRNA presence in
serum was described for the ﬁrst time in March 2008, in
patientswithdiﬀuselargeB-celllymphoma[52].Subsequent
to this, a small number of studies have reported similarly,
on the presence of miRNA in circulation and their potential
for use as novel biomarkers for diseases and physiological
statesincludingmalignancy,diabetesmellitusandpregnancy
[53–55]. However these studies have been limited by small
numbers and inconsistencies in methodologies [56]. This
concept needs extensive investigation to validate the theory.
To date no work has been published on the role of circulating
miRNAs in breast cancer—an area where, if feasible, their
use as novel minimally invasive biomarkers would be an
incredible breakthrough in our management of this disease.
4. Therapeutic Potential
The association of aberrant miRNA expression with tumori-
genesis and the functional analysis of speciﬁc miRNAs illus-
trate the feasibility of using miRNAs as targets of therapeutic
intervention. Anti-miRNA 2-O-methyl or locked nucleic
acid oligonucleotides used to inactivate oncomirs such as
miR-21inbreasttumorsmaytapertumorgrowth[17].Anti-
miR-21-induced reduction in tumor growth, interestingly,
was also shown by Si et al. to be potentiated by the addition
of the chemotherapeutic agent topotecan, an inhibitor of
DNA topoisomerase I. This suggests that suppression of the
oncogenic miR-21 could sensitize tumor cells to anticancer
therapy, which is an exciting prospect for patients exhibiting
a poor response to primary chemotherapy. Conversely, the
inductionoftumorsuppressormiRNAexpressionusingviral
or liposomal delivery of tissue-speciﬁc tumor suppressors to
aﬀected tissue may result in the prevention of progression,
or even shrinking, of breast tumors. Tumor suppressor
miRNA induction has also been shown to be subject
to epigenetic control. Using chromatin remodelling drugs
to simultaneously inhibit DNA methylation and histone
deacetylation, epigenetic alterations in cancer and normal
cells were manipulated by Saito et al. [57], who showed that
certain miRNAs were upregulated in tumor cells but not in
normal cells. MiR-127, which exhibited reduced expression
in 75% of human cancer cells tested, was signiﬁcantly
upregulated after treatment. The induction of this miRNA
was associated with downregulation of the proto-oncogene
BCL6, suggesting a cancer-protective eﬀect for miR-127 and
a novel therapeutic strategyforthe prevention and treatment
of malignancy. This concept of inducing tumour suppressor
miRNA expression has been termed “miRNA Replacement
Therapy”; in anticipation of the promising clinical potential
it holds.
5. Conclusion
The involvement of miRNAs in the initiation and pro-
gression of human malignancy holds great potential for
new developments in current diagnostic and therapeutic
strategies in the management of patients with breast cancer.
Much of the work on microRNAs is still in its infancy and
requires further exploration so that we may better under-
stand their role in tumorigenesis. This scientiﬁc endeavour6 Journal of Oncology
will undoubtedly lead to exciting developments in the future
management of breast cancer. As the functional roles of
miRNAs in cancer biology are further uncovered we predict
that; circulating miRNAs will serve as novel minimally inva-
sive biomarkers for breast and other cancers, that improved
methods of stratifying and subclassifying breast cancers will
lead to tailored and individualized therapeutic regimens,
thus sparing many patients from toxic eﬀects of treatments
from which they would derive no beneﬁt. There is obviously
great demand now for further intensive research into the
identiﬁcation of novel miRNAs, the elucidation of their
mRNA targets, and an understanding of their functional
eﬀects, so as to improve our knowledge of the roles of these
novel biomarkers in carcinogenesis and to expose their true
potential as therapeutic agents.
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